RxDoctor Payments Data

Mansel Kevwitch, MD

Urology · Mount Vernon, WANPI 1568540771

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,138 of the $9,069 with a category attached, or 78.7%. It is spread thinly across 39 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,396 and has fallen 95.6% since, to $148 in 2025.

$9,069in general payments, 2019–2025

Across 234 payments — averaging $38.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Myriad Genetic Laboratories, Inc.$1K
  • Boston Scientific$1K
  • Johnson & Johnson$990
  • Telix Pharmaceuticals$344
  • Janssen Scientific Affairs, LLC$240
  • plus $3K from 33 others

What the payments were for

  • Travel & lodging$1,63118%
  • Food & beverage$7,13879%
  • Education$3013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,069 in reported general payments places this provider in the 80th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$84,335
Medicare patients
324
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate33$105,363
GemtesaVibegron20$22,519
OsphenaOspemifene21$9,711
MyrbetriqMirabegron20$9,462
Tamsulosin Hcl422$9,460
Potassium Citrate ErPotassium Citrate32$4,789
Estradiol44$3,522
Finasteride202$3,279
Alfuzosin Hcl ErAlfuzosin Hcl91$2,238
Dutasteride26$729
Methylprednisolone15$695
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$467
Cephalexin31$327
Prednisone27$189
Ciprofloxacin Hcl29$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Janssen Scientific Affairs, LLCAbiraterone Acetate$240$105,36333 claims
Sumitomo Pharma America, Inc.Gemtesa$224$22,51920 claims
Astellas Pharma US IncMyrbetriq$98$9,46220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 274 urology providers in Washington.

Other urology in Mount Vernon

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →